Guenther Kaiser
- No significant clinical drug-drug interaction potential with indacaterolBy Sheryl Perry, Paul Goldsmith, Sivakumar Vaidyanathan, Prafulla Bhad, Heidi Einolf, Ralph Woessner, Guenther Kaiser, Simon Jennings and Beverley PattersonSheryl Perry1DMPK, Novartis Institutes of BioMedical Research, Horsham, United KingdomPaul Goldsmith1DMPK, Novartis Institutes of BioMedical Research, Horsham, United KingdomSivakumar Vaidyanathan2Translational Sciences, Novartis Institutes of BioMedical Research, Hyderabad, IndiaPrafulla Bhad2Translational Sciences, Novartis Institutes of BioMedical Research, Hyderabad, IndiaHeidi Einolf3DMPK, Novartis Institutes of BioMedical Research, East Hanover, NJ, United StatesRalph Woessner4DMPK, Novartis Institutes of BioMedical Research, Basel, SwitzerlandGuenther Kaiser4DMPK, Novartis Institutes of BioMedical Research, Basel, SwitzerlandSimon Jennings5Development, Novartis Horsham Research Centre, Horsham, United KingdomBeverley Patterson1DMPK, Novartis Institutes of BioMedical Research, Horsham, United Kingdom
- Efficient deposition and absorption of orally inhaled indacaterol in the lungsBy Ruth Lock, Deidre Price, Sanjeev Khindri, Ralph Woessner, Markus Weiss, Hisanori Hara, Ilona Pylvaenaeinen and Guenther KaiserRuth Lock1Translational Sciences, Novartis Institutes for Biomedical Research, Horsham, United KingdomDeidre Price1Translational Sciences, Novartis Institutes for Biomedical Research, Horsham, United KingdomSanjeev Khindri1Translational Sciences, Novartis Institutes for Biomedical Research, Horsham, United KingdomRalph Woessner2Translational Sciences, Novartis Pharma AG, Basel, SwitzerlandMarkus Weiss2Translational Sciences, Novartis Pharma AG, Basel, SwitzerlandHisanori Hara2Translational Sciences, Novartis Pharma AG, Basel, SwitzerlandIlona Pylvaenaeinen3Integrated Information Sciences, Novartis Pharma AG, Basel, SwitzerlandGuenther Kaiser2Translational Sciences, Novartis Pharma AG, Basel, Switzerland
- Lack of effect of mild and moderate hepatic impairment or UGT1A1 genotype on the pharmacokinetics of inhaled indacaterolBy Paul Goldsmith, Sheryl Perry, Handan He, Ralph Woessner and Guenther KaiserPaul Goldsmith1DMPK, NIBR, Horsham, West Sussex, United KingdomSheryl Perry1DMPK, NIBR, Horsham, West Sussex, United KingdomHandan He2DMPK, NIBR, East Hanover, NJ, United StatesRalph Woessner3DMPK, NIBR, Basel, SwitzerlandGuenther Kaiser3DMPK, NIBR, Basel, Switzerland
- Small impact of mild and moderate renal impairment on the pharmacokinetics of inhaled NVA237By Romain Sechaud, Anton Drollmann, Hisanori Hara, Rajesh Karan, Craig Boulton, Lilla Di Scala, Andrey Dmitriev, Svetlana Villevalde, Zhanna Kobalava and Guenther KaiserRomain Sechaud1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandAnton Drollmann1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandHisanori Hara1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandRajesh Karan2Translational Sciences, Novartis Institutes for BioMedical Research, Hyderabad, IndiaCraig Boulton3Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomLilla Di Scala4Biostatistics, Novartis Pharma AG, Basel, SwitzerlandAndrey Dmitriev5Center of Nephrology and Dialysis, Moscow City Hospital, Moscow, Russian FederationSvetlana Villevalde6Center of Applied Pharmacology, Moscow City Hospital, Moscow, Russian FederationZhanna Kobalava6Center of Applied Pharmacology, Moscow City Hospital, Moscow, Russian FederationGuenther Kaiser1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland
- Pharmacokinetics (PK) of single doses of mometasone furoate (MF) delivered via the Breezhaler® (BH) and Twisthaler® (TH) devices in healthy subjectsBy Soniya Vaidya, Sanjeev Khindri, Jess Robinson, Tom Smith, Baldur Magnusson, Guenther Kaiser, Ulf Malmqvist and Beverley PattersonSoniya Vaidya1Translational Sciences, Novartis Institutes for BioMedical Research, Cambridge, United StatesSanjeev Khindri2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomJess Robinson2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomTom Smith3Translational Sciences, Novartis Institutes for BioMedical Research, East Hanover, United StatesBaldur Magnusson4Integrated Information Sciences, Novartis Pharma AG, Basel, SwitzerlandGuenther Kaiser5Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandUlf Malmqvist6Clinical Research and Trial Centre, Skane University Hospital, Lund, SwedenBeverley Patterson2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United Kingdom
- Efficient deposition and sustained lung concentrations of NVA237 after inhalation via the Breezhaler® device in manBy Romain Sechaud, Manish Sudershan, Sheryl Perry, Hisanori Hara, Anton Drollmann, Rajesh Karan, Lilla Di Scala, Shibadas Biswal, Beverley Patterson and Guenther KaiserRomain Sechaud1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandManish Sudershan2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomSheryl Perry2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomHisanori Hara1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandAnton Drollmann1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandRajesh Karan3Translational Sciences, Novartis Institutes for BioMedical Research, Hyderabad, IndiaLilla Di Scala4Biostatistics, Novartis Pharma AG, Basel, SwitzerlandShibadas Biswal3Translational Sciences, Novartis Institutes for BioMedical Research, Hyderabad, IndiaBeverley Patterson2Translational Sciences, Novartis Institutes for BioMedical Research, Horsham, United KingdomGuenther Kaiser1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland
- No relevant drug-drug interaction between inhaled NVA237 and oral cimetidineBy Romain Sechaud, Swati Dumitras, Anton Drollmann, Hisanori Hara, Rajesh Karan, Parasar Pal, Sivakumar Vaidyanathan and Guenther KaiserRomain Sechaud1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandSwati Dumitras1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandAnton Drollmann1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandHisanori Hara1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, SwitzerlandRajesh Karan2Translational Sciences, Novartis Institutes for BioMedical Research, Hyderabad, IndiaParasar Pal3Biostatistics, Novartis Institutes for BioMedical Research, Hyderabad, IndiaSivakumar Vaidyanathan2Translational Sciences, Novartis Institutes for BioMedical Research, Hyderabad, IndiaGuenther Kaiser1Translational Sciences, Novartis Institutes for BioMedical Research, Basel, Switzerland
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.